export interface BlogPost {
  slug: string;
  title: string;
  excerpt: string;
  date: string;
  author: string;
  authorRole: string;
  readTime: string;
  category: string;
  tags: string[];
  heroImage?: string;
  content: string; // Markdown-ish content (rendered as HTML sections)
}

export const blogPosts: BlogPost[] = [
  {
    slug: 'ai-governance-life-sciences-2026',
    title: 'AI Governance in Life Sciences: What Regulators Expect in 2026',
    excerpt:
      'From the EU AI Act to FDA draft guidance on AI/ML, regulated companies face a new reality. Here\'s the practical governance framework you need — not the theoretical one consultants sell.',
    date: '2026-03-05',
    author: 'GxP Agents',
    authorRole: 'AI Governance Practice',
    readTime: '8 min read',
    category: 'AI Governance',
    tags: ['ai-governance', 'eu-ai-act', 'fda', 'compliance', 'life-sciences'],
    content: `
The conversation around AI governance in life sciences has shifted dramatically. It's no longer "should we govern AI?" — it's "how do we govern AI before the regulators tell us we're doing it wrong?"

## The Regulatory Landscape Has Changed

Three forces converged in 2025-2026:

**The EU AI Act** classified certain life sciences AI applications as "high-risk," requiring conformity assessments, quality management systems, and post-market monitoring. If your AI touches patient safety, clinical decisions, or regulatory submissions — you're in scope.

**FDA's draft guidance on AI/ML-enabled medical devices** expanded beyond SaMD to include AI used in manufacturing, quality, and pharmacovigilance workflows. The message is clear: if AI influences GxP decisions, it needs governance.

**ICH guidance** continues to evolve, with Q2(R2) and emerging digital health guidelines acknowledging AI as part of the pharmaceutical quality system.

## What a Real Governance Framework Looks Like

Forget the 40-page policy documents that sit in SharePoint. Effective AI governance in life sciences requires five operational capabilities:

### 1. AI Use Case Registry
Every AI application — from a simple classification model to a generative drafting assistant — needs to be inventoried with its risk classification, intended use, data sources, and human oversight controls.

### 2. Validation Strategy Aligned to Risk
Not every AI needs the same validation rigor. A risk-based approach (aligned with CSA thinking) means your deviation classifier gets a different validation path than your batch release prediction model.

### 3. Change Control for AI
Models drift. Data distributions shift. Prompts get updated. Your change control process needs to account for AI-specific changes that traditional software validation wasn't designed for.

### 4. Human-in-the-Loop Architecture
Every AI output that influences a GxP decision needs a defined human review point. Not as a checkbox — as an architected workflow step with clear accountability.

### 5. Audit Trail and Explainability
When an inspector asks "why did the AI recommend this?" you need an answer that traces from the model output back through the data, the logic, and the human decision that followed.

## The Gap Between Theory and Practice

Most life sciences companies have AI governance policies. Few have AI governance operations. The difference?

- **Policy**: "All AI applications shall be validated per our SOP."
- **Operations**: A living registry of 47 AI use cases, each with a validated status, a risk owner, and a review cadence.

GxP Agents was built for the operations side. Every agent in our platform operates within a governance framework that includes use case registration, human-in-the-loop controls, complete audit trails, and risk-appropriate validation.

## Start Here

If you're building your AI governance program, start with three questions:

1. **Do you know how many AI applications are running in your organization?** (Most companies undercount by 3-5x when you include spreadsheet models, RPA bots, and embedded ML features.)

2. **Can you trace any AI-influenced decision back to the model, the data, and the human who approved it?** (If not, you have an audit risk.)

3. **Does your change control system account for model updates, prompt changes, and training data shifts?** (If not, you have a compliance risk.)

The companies that answer these questions now — before the next FDA inspection or EU AI Act enforcement action — will be the ones that turn AI governance from a cost center into a competitive advantage.
    `,
  },
  {
    slug: 'why-your-qms-is-already-obsolete',
    title: 'Why Your QMS Is Already Obsolete (And What to Do About It)',
    excerpt:
      'Quality Management Systems were designed for a world of paper and periodic audits. AI-driven quality intelligence is the next evolution — and it\'s already here.',
    date: '2026-03-04',
    author: 'GxP Agents',
    authorRole: 'Quality Intelligence',
    readTime: '6 min read',
    category: 'Quality',
    tags: ['quality', 'qms', 'ai-automation', 'deviation-management', 'inspection-readiness'],
    content: `
Let's be honest about something the quality industry doesn't like to say out loud: most QMS platforms are glorified document management systems with workflow engines bolted on.

They capture deviations after they happen. They route CAPAs through approval chains. They store SOPs. And they generate reports that tell you what went wrong last quarter.

None of that is intelligence. It's record-keeping.

## The Problem Isn't Your QMS Platform

TrackWise, Veeva Vault Quality, MasterControl, ETQ — they're fine platforms. The problem is what they can't do:

- **They can't predict** which deviations will recur before the root cause investigation even starts
- **They can't see patterns** across 10,000 deviation records that a human reviewer would take weeks to analyze
- **They can't draft** investigation narratives that are consistent with your previous regulatory submissions
- **They can't assess** inspection readiness continuously — only when someone runs a report

## What AI-Driven Quality Intelligence Looks Like

Imagine your quality system doing this:

**Monday morning:** An AI agent scans every open deviation, maps them against historical patterns, and flags three that show signature similarity to a recurring issue you closed six months ago. Before your quality team even opens their laptops.

**During a batch release:** Instead of a QA reviewer reading every page of a 200-page batch record, an AI agent reviews the execution data, flags only the exceptions that deviate from historical norms, and presents a 2-page summary of what needs human attention.

**Before an inspection:** Instead of a war room and three weeks of preparation, an AI agent continuously monitors your inspection readiness score across QMS, TMF, training, and supplier quality — and alerts you to gaps when they form, not when an inspector finds them.

## This Isn't Science Fiction

Every capability described above is operationally feasible today. The technology exists. The question is architecture and governance:

- How do you layer AI intelligence onto your existing QMS without ripping and replacing?
- How do you validate AI-assisted quality decisions for regulatory defensibility?
- How do you maintain the human-in-the-loop controls that regulators require?

These are design problems, not technology problems. And they're exactly what GxP Agents was built to solve.

## The Three-Year Window

Companies that build AI-driven quality intelligence in 2026-2027 will have a structural advantage. Not because the AI is magic — because the historical data they'll accumulate, the patterns their models will learn, and the operational muscle memory they'll develop will compound.

Companies that wait until 2028-2029 will be playing catch-up against competitors whose AI has already learned their industry's quality patterns.

The QMS isn't dead. But the QMS as your primary quality intelligence tool? That era is over.
    `,
  },
  {
    slug: 'pharma-cybersecurity-beyond-checkbox',
    title: 'Pharma Cybersecurity: Beyond the Checkbox Audit',
    excerpt:
      'Life sciences companies treat cybersecurity like a compliance exercise. The threat actors targeting your clinical data and manufacturing systems don\'t care about your audit score.',
    date: '2026-03-03',
    author: 'GxP Agents',
    authorRole: 'Cybersecurity & TPRM Practice',
    readTime: '7 min read',
    category: 'Cybersecurity',
    tags: ['cybersecurity', 'pharma', 'tprm', 'gxp', 'ransomware', 'life-sciences'],
    content: `
Here's a number that should keep every pharma CISO up at night: **68% of life sciences companies experienced a cybersecurity incident affecting GxP systems in the past 24 months.** Not IT systems — GxP systems. Manufacturing execution. Laboratory information management. Clinical trial databases.

The response from most companies? Another SOC 2 audit. Another vendor questionnaire. Another checkbox.

## The Checkbox Problem

Traditional cybersecurity in pharma looks like this:

1. Annual risk assessment (usually a spreadsheet)
2. Vendor security questionnaires (usually ignored after onboarding)
3. Penetration test (usually scoped to exclude production systems)
4. Compliance audit (usually retrospective)

The gap between this approach and actual security is where breaches happen.

## What Changes With AI-Driven Security

AI-powered cybersecurity for life sciences isn't about replacing your SOC team. It's about giving them the context they're currently missing:

### Continuous Vendor Risk Monitoring
Instead of reviewing vendor security annually, AI agents continuously monitor vendor control posture, breach notifications, financial health indicators, and operational signals. When your CDMO's security rating drops, you know in hours — not months.

### GxP-Aware Threat Intelligence
Generic threat feeds don't know that your LIMS server is a Tier 1 GxP system. AI agents that understand your system classification can prioritize alerts based on GxP impact, not just CVSS scores.

### Access Intelligence
Who has access to what, and is it appropriate? AI continuously analyzes access patterns, identifies privilege creep, and flags anomalous behavior patterns before they become incidents.

### Third-Party Risk Quantification
Your third-party risk isn't just about SOC reports. It's about understanding which vendors have access to GxP data, which ones represent single points of failure, and which ones would trigger a regulatory notification if breached.

## The Convergence of Cyber and Quality

Here's what makes pharma cybersecurity different from every other industry: a cybersecurity incident in a GxP environment is also a quality incident. A compromised manufacturing system isn't just an IT ticket — it's a potential product quality issue that may require regulatory notification.

The companies that understand this convergence are building integrated risk views that span quality, cyber, and compliance. The companies that don't are managing these as separate silos, creating gaps that both threat actors and regulators will find.

## Start With Visibility

Before you buy another tool or hire another consultant, answer one question: **Can you produce, in under 30 minutes, a complete list of every third-party vendor with access to GxP data, their current security posture, and the last time their controls were validated?**

If not, that's your starting point. Not more policy. Visibility.
    `,
  },
  {
    slug: 'samd-ai-governance-what-fda-wants',
    title: 'SaMD + AI: What the FDA Actually Wants to See',
    excerpt:
      'Software as a Medical Device meets artificial intelligence. The intersection is where the biggest regulatory opportunities — and risks — live for diagnostics and digital health companies.',
    date: '2026-03-01',
    author: 'GxP Agents',
    authorRole: 'Regulatory Intelligence',
    readTime: '9 min read',
    category: 'Regulatory',
    tags: ['samd', 'fda', 'ai-ml', 'digital-health', 'regulatory', 'diagnostics'],
    content: `
If you're building diagnostic algorithms, clinical decision support tools, or any software that uses AI/ML to inform medical decisions, you're operating at the intersection of two of the most actively evolving regulatory domains: Software as a Medical Device (SaMD) and AI/ML governance.

The FDA has been remarkably transparent about where this is heading. The question is whether companies are listening — and more importantly, whether they're building for it.

## The FDA's Predetermined Change Control Plan

The biggest regulatory innovation in SaMD + AI isn't a new rule. It's the concept of a **Predetermined Change Control Plan (PCCP)** — a framework that allows manufacturers to describe anticipated modifications to their AI/ML algorithm and get them pre-authorized.

Think about what this means: instead of submitting a new 510(k) every time your model is retrained, you describe the types of changes you'll make, the validation methodology you'll use, and the performance thresholds that trigger regulatory notification. If the change fits within your PCCP, you implement it. If it doesn't, you submit.

## What This Means Practically

For companies building AI-powered diagnostics or clinical decision support:

### Your Algorithm Lifecycle Needs Governance
Every model version, every training data update, every performance metric needs to be tracked, validated, and auditable. This isn't optional anymore — it's the price of entry.

### You Need Real-World Performance Monitoring
Post-market surveillance for SaMD means continuously monitoring how your algorithm performs in the real world. Not just accuracy — bias, drift, edge cases, and failure modes.

### Your Data Pipeline Is Your Regulatory Submission
The FDA wants to see your training data, your validation methodology, your test datasets, and your performance benchmarks. If your data pipeline isn't governed, your regulatory submission has a gap.

### Human Oversight Must Be Architected
For AI/ML-enabled SaMD, the FDA expects clear documentation of when human review is required, how human override works, and what happens when the AI and the clinician disagree.

## The GxP Agents Approach

We built our regulatory agents specifically for this intersection. The Regulatory Affairs domain includes use cases for:

- **Submission readiness QC** that understands AI/ML-specific documentation requirements
- **Regulatory intelligence** that tracks evolving SaMD guidance across FDA, EU MDR, and global health authorities
- **Labeling intelligence** that maps AI-specific claims and indications across markets

For diagnostics companies navigating this space: the regulatory framework is becoming clearer, not more ambiguous. The companies that build governance into their AI development lifecycle now will have a significant advantage when the final guidance lands.
    `,
  },
];

export function getBlogBySlug(slug: string): BlogPost | undefined {
  return blogPosts.find((p) => p.slug === slug);
}
